1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 United States Platelet Rich Plasma Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product Type
6.1 Pure Platelet-Rich Plasma (P-PRP)
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Leukocyte- and Platelet-Rich Plasma (LPRP)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Leukocyte- and Platelet-Rich Fibrin (L-PRF)
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Pure Platelet-Rich Fibrin (P-PRF)
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Origin
7.1 Autologous PRP
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Homologous PRP
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Allogeneic PRP
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Application
8.1 Orthopedics
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Cosmetic Surgery and Dermatology
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Neurosurgery
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 General Surgery
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Cardiothoracic Surgery
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Urology
8.6.1 Market Trends
8.6.2 Market Forecast
8.7 Ophthalmology
8.7.1 Market Trends
8.7.2 Market Forecast
8.8 Others
8.8.1 Market Trends
8.8.2 Market Forecast
9 Market Breakup by End User
9.1 Hospitals and Clinics
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Research Institutes
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Others
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Region
10.1 Northeast
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Midwest
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 South
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 West
10.4.1 Market Trends
10.4.2 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Arteriocyte Medical Systems Inc. (Isto Technologies II LLC)
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 SWOT Analysis
15.3.2 Arthrex Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.3 Depuy Synthes Inc. (Johnson & Johnson)
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.4 Dr Prp USA LLC
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.5 EmCyte Corporation
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.6 Exactech Inc.
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.7 Glofinn America LLC (Glofinn Co. Ltd.)
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.8 Regen Lab USA LLC
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.9 Stryker Corporation
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Terumo BCT Inc. (Terumo Corporation)
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 ThermoGenesis Holdings Inc.
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis
15.3.12 Zimmer Biomet Holdings Inc.
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials
15.3.12.4 SWOT Analysis
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/